Referencia número: HY-138300

Copy Link Print Information

ALC-0159

19 Cited Publications

Revisión del cliente

Based on 19 publication(s) in Google Scholar

ALC-0159, a polyethylene glycol (PEG) lipid conjugate, could be used as vaccine excipient.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.93%
No. CAS: 1849616-42-7
Fòrmula: (C₂H₄O)nC₃₁H₆₃NO₂

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

ALC-0159 Chemical Structure

No. CAS: 1849616-42-7

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- In Vitro
Chemical Information
Publications (19)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

ALC-0159, a polyethylene glycol (PEG) lipid conjugate, could be used as vaccine excipient^[1].

In Vitro

Preparation of Lipid Nanoparticles

Here we provide lipid molar ratios for LNPs in FDA-approved BNT162b2 (a COVID-19 mRNA vaccine). The molar ratio of lipids in this formulation is ALC-0315 : DSPC : Cholesterol : ALC-0159 = 46.3 : 9.4 : 42.7 : 1.6, and RNA to lipid weight ratio is 0.05 (wt/wt)^[1].

A. Lipid Mixture Preparation

1. Dissolve lipids in ethanol and prepare 10 mg/m stock solutions. The lipid stock solutions can be stored at 20°C for later use.

Note 1: The ionizable lipid is usually a liquid. Due to the viscosity, it should always be weighed rather than relying on the autopipette volume.

Note 2: Cholesterol in solution should be kept warm (>37°C) to maintain fluidity. Transfer the cholesterol solution promptly to avoid cooling.

2. Prepare the lipid mixture solution as described. For each mL of lipid mixture add the following: 560 μL of 10mg/mL ALC-0315 (HY-138170), 261 μL of 10mg/mL Cholesterol (HY-N0322), 117 μL of 10mg/mL DSPC (HY-W040193), and 62 μL of 10mg/mL ALC-0159 (HY-138300). Mix the solutions thoroμghly to achieve a clear solution. This mixture contains 10 mg of total lipid.

Note 3: The choice of lipids and ratios may be changed as desired and this will affect the LNP properties (size, polydispersity, and efficacy) and the amount of mRNA required.

B. mRNA Preparation

1. Prepare a 166.7 μg/mL mRNA solution with 100 mM pH 5 sodium acetate buffer.

Note 4: The lipid:mRNA weight ratio influences the encapsulation efficiency. Other weight ratios may be prepared as alternative formulations and should be adjusted accordingly by user.

C. Mixing

There are three commonly used methods to achieve rapid mixing of the solutions: the pipette mixing method, the vortex mixing method, and the microfluidic mixing method. All these mixing methods can be used for various applications.

It is important to note that pipette mixing method and vortex mixing method may yield more heterogeneous LNPs with lower encapsulation efficiencies and is prone to variability. Microfluidic devices enable rapid mixing in a highly controllable, reproducible manner that achieves homogeneous LNPs and high encapsulation efficiency. Within these devices, the ethanolic lipid mixture and aqueous solution are rapidly combined in individual streams. LNPs are formed as the two streams mix and are then collected into a single collection tube.

1. Pipette Mixing Method:

1.1. Pipette 3 mL of the mRNA solution and quickly add it into 1 mL of the lipid mixture solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.) Pipette up and down rapidly for 20-30 seconds.

1.2. Incubate the resulting solution at room temperature for up to 15 minutes.

1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

2. Vortex Mixing Method:

1.1. Vortex 3 mL of mRNA solution at a moderate speed on the vortex mixer. Then, Quickly add 1 mL of the lipid mixture solution into the vortexing solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.). Continue vortexing the resulting dispersion for another 20-30 seconds.

1.2. Incubate the resulting solution at room temperature for up to 15 minutes.

1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

3. Microfluidic Mixing Method:

1.1 The 3 mL of mRNA buffer solution and 1 mL of the lipid mixture solution were mixed at a total flow rate of 12 mL/min in a microfluidic device (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.).

Note 5: Parameters such as the flow rate ratio and total flow rate can be altered to fine-tune LNPs.

1.2. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

Reference

1. Curr Issues Mol Biol. 2022 Oct 19;44(10):5013-5027.

2. Curr Protoc. 2023;3(9):e898.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 1849616-42-7
Appearance Solid
Fòrmula (C₂H₄O)nC₃₁H₆₃NO₂
Color White to off-white
SMILES

CCCCCCCCCCCCCCN(C(COCCOC)=O)CCCCCCCCCCCCCC.[n]
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (19)

All Flow CytometryBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Science

Single intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction. [Abstract]

2026 Mar 5;391(6789):edau9394. PMID: 41785353
Mol Cancer

Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity. [Abstract]

2025 Jan 13;24(1):12. PMID: 39806486

ALC-0159 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Jan 13;24(1):12. [Abstract]

LNP-M with DMG-PEG 2000, ALC-0159, or DSPE to deliver pGFP.

ALC-0159 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Jan 13;24(1):12. [Abstract]

LNP-M with DMG-PEG 2000, ALC-0159, or DSPE to deliver pGFP.
Mater Today

2026 May 22;98:103389.
ACS Nano

Enhanced Local Delivery of Engineered IL-2 mRNA by Porous Silica Nanoparticles to Promote Effective Antitumor Immunity. [Abstract]

2023 Sep 12;17(17):17554-17567. PMID: 37643221
Adv Sci (Weinh)

A Single-Dose mRNA Vaccine Employing Porous Silica Nanoparticles Induces Robust Immune Responses Against the Zika Virus. [Abstract]

2024 Sep;11(35):e2404590. PMID: 39010673
J Control Release

Functional lipid nanoparticles for safe delivery of macromolecular antibiotics to gram-negative bacteria. [Abstract]

2025 Aug 10:384:113907. PMID: 40451556
Small Methods

Cholesterol-Derived Mannosylated Polypeptide-Formed Lipid Nanoparticles for Efficient in Vivo mRNA Delivery. [Abstract]

2025 Jun;9(6):e2401712. PMID: 40256901
NPJ Vaccines

A self-amplifying mRNA vaccine expressing PRV gD induces robust immunity against virulent mutants. [Abstract]

2025 Aug 14;10(1):193. PMID: 40813770
Mol Ther Nucleic Acids

A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines. [Abstract]

2026 Mar 5;37(2):102886. PMID: 41883582
Biomacromolecules

Replacing PEG-Lipid with Amphiphilic Polycarbonates in mRNA-Loaded Lipid Nanoparticles: Impact of Polycarbonate Structure on Physicochemical and Transfection Properties. [Abstract]

2025 Jun 9;26(6):3563-3575. PMID: 40347133
Eur J Pharm Biopharm

Interactions between mRNA lipid nanoparticles and immune cells in fresh human whole blood. [Abstract]

2026 Jun 9:115146. PMID: 42264006
Nanomedicine

Quantitative analysis of mRNA-lipid nanoparticle stability in human plasma and serum by size-exclusion chromatography coupled with dual-angle light scattering. [Abstract]

2024 Jun:58:102745. PMID: 38499167

ALC-0159 purchased from MedChemExpress. Usage Cited in: Nanomedicine. 2024 Jun:58:102745. [Abstract]

LC-MS/MS quantitation of mRNA-LNP composition during degradation in serum and plasma. (A) Overlaid PRM chromatograms of cholesterol (369.65 → 147.16), DSPC (790.82 → 184.13), ALC-0315 (766.91 → 510.62), and ALC-0159 (0.1 nM) (1184.10 → 494.62). Quantities injected: 1, 2, 4 and 8 pmol of DSPC, ALC-0315 and ALC-0159; 10, 20, 40 and 80 pmol of cholesterol.
J Gen Virol

Broadly neutralizing monoclonal antibodies derived from mRNA LNP immunization exhibit potent neutralizing ability against JN.1, KP.3.1.1 and XEC new Omicron variants. [Abstract]

2026 Apr;107(4). PMID: 42030071
Vaccines

Immunogenic Comparison of Nucleic Acid-Based Vaccines Administered by Pyro-Drive Jet Injector. [Abstract]

2024 Jul 9;12(7):757. PMID: 39066395
Immunol Cell Biol

Age-related differences in mRNA vaccine immunogenicity and adjuvancy. [Abstract]

2026 Mar 12. PMID: 41819108
bioRxiv

2026 May 4.
bioRxiv

2025 Jun 17.
Research Square Preprint

2023 Sep 12.
bioRxiv

2023 Jun 10.

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : ≥ 50 mg/mL

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (272 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. S Moein Moghimi, et al. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Mol Ther. 2021 Mar 3;29(3):898-900. [Content Brief]

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

ALC-0159

19 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

ALC-0159

Publications Citing Use of MedChemExpress (MCE) ALC-0159

Actividad biológica

Chemical Information

Publications (19)

Solvente y solubilidad

Pureza y Documentación

Referencias

Calculators

Help & FAQs

ALC-0159 Related Classifications

HY-138300 Related Classifications